QuantaMatrix Inc

QuantaMatrix Inc has a strong liquidity position with cash and equivalents of KRW 38.5 billion, representing 73% of total assets, and a current ratio of 4.27, well above the industry median of 1.8. The price-to-book ratio of 1.96 suggests market valuation is in line with tangible asset base. However, the company's capital structure shows negative operating and net income of KRW -1.65 trillion and KRW -1.95 trillion respectively, with a debt-to-equity ratio of 0.24, indicating limited leverage but also weak profitability. Profitability metrics show significant underperformance relative to industry norms. Return on equity of -48.6% and return on assets of -36.9% are far below the industry median ROE of 12.3% and ROA of 7.1%. Gross margin of 43.7% (KRW 1.61 billion gross profit on KRW 3.69 billion revenue) is near the industry median of 44.2%, but operating margin of -447% (KRW -1.65 billion operating loss) is a severe outlier. The company operates as a single-segment business with 100% revenue concentration in its IVD medical devices business. Geographic exposure is entirely domestic, with all revenue generated in South Korea. This creates high concentration risk, as the company lacks geographic diversification to buffer against regional economic or regulatory shocks. Growth trajectory shows mixed signals. Revenue of KRW 3.69 billion represents a 12.4% year-over-year increase, but operating losses have expanded by 23.1% YoY. The company is investing in R&D with capital expenditures of KRW -677 million, but free cash flow of KRW -1.79 billion indicates insufficient cash generation to fund operations and growth. Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of KRW -1.51 billion and free cash flow of KRW -1.79 billion create ongoing cash burn. No dilution sources were identified in filings, but the company maintains a shelf registration for potential future equity raises. Recent 10-K filings show the company is advancing its sepsis diagnostic platform through clinical trials and expanding its molecular immunodiagnostic testing portfolio. Management has emphasized strategic partnerships with South Korean hospitals to increase market penetration, though no material contracts were disclosed in the latest quarterly reports.